Indivior consensus picture on Tuesday, shares on the London listing

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 09:20.

Indivior (GB00BYZ0C031) starts this Tuesday with attention on the analyst consensus for its London-listed shares. The company remains a specialised player in addiction treatment, with its stock traded on the London Stock Exchange in the pharmaceuticals sector.

What analysts focus on

Coverage of Indivior generally centers on its exposure to opioid use disorder therapies and related legal and regulatory risks, with earnings estimates shaped by prescription trends and settlements. Research houses look closely at operating margins and cash generation when setting ratings and price targets.

Analyst models for Indivior typically incorporate assumptions on patient volumes in the United States and other key markets, where reimbursement frameworks and formulary decisions by health plans directly affect revenue. The distribution of recommendations often reflects a balance between growth potential from new formulations and litigation overhangs.

Consensus estimates and peers

On a Tuesday consensus focus, investors compare Indivior’s projected earnings and revenue growth to international peers in the addiction and mental health treatment space, such as larger US-based pharmaceutical groups. The stock’s valuation multiples, including price-to-earnings ratios based on forward estimates, are used to position the shares within that peer group.

In this context, London investors monitor any changes in target prices or rating stances as signaled by updates from major global research houses, including firms such as Goldman Sachs, JPMorgan or UBS, even though the exact current ratings and target levels are not cited here due to missing live data access.

The products behind the stock

Indivior’s business model focuses on medications for opioid use disorder and related conditions, with representative products including buprenorphine-based treatments. Revenue depends on prescribing activity, pricing agreements with payers and ongoing investment in new formulations to extend intellectual property protection.

Where the Indivior shares trade today

The Indivior shares (GB00BYZ0C031) are listed on the London Stock Exchange in pounds sterling. A precise live price and timestamp for 2026-06-30, 09:20, cannot be stated here because real-time quote data is not accessible in this response.

Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any transaction. All data are based on publicly available information, which may be incomplete or outdated. Investors should conduct their own research and, if necessary, seek independent professional advice.